胆囊治疗的全球市场 - 2022年～2029年

本报告提供全球胆囊治疗市场相关调查，提供市场概要，以及各疾病，不同治疗，各终端用户，各地区趋势，竞争情形，及加入此市场的主要企业简介等资讯。

目录

第1章 胆囊治疗市场调查手法和范围

第2章 胆囊治疗市场-市场定义和概要

第3章 胆囊治疗市场-摘要整理

• 各疾病市场明细
• 不同治疗市场明细
• 各终端用户市场明细
• 各地区市场明细

第4章 胆囊治疗市场-市场动态

• 影响市场的要素
  • 促进因素
  • 阻碍因素
  • 市场机会
  • 影响分析

第5章 胆囊治疗市场-产业分析

• 波特的五力分析
• 供应链分析
• 价格分析
• 法规分析
• 未满足需求

第6章 胆囊治疗市场-COVID-19分析

第7章 胆囊治疗市场-各疾病

• 简介
• 市场规模分析，及与前一年同期比较成长分析(%)、各疾病
• 市场魅力指数，各疾病
  • 胆囊结石
  • 胆囊炎
  • 胆囊结石腹绞痛
  • 胆结石
  • 胆囊息肉
  • 胆囊癌
  • 其他

第8章 胆囊治疗市场-不同治疗

• 简介
• 市场规模分析，及与前一年同期比较成长分析(%)、不同治疗
• 市场魅力指数，不同治疗
  • 手术
  • 药物
  • 其他

第9章 胆囊治疗市场-各终端用户

• 简介
  • 市场规模分析，及与前一年同期比较成长分析(%)、各终端用户
  • 市场魅力指数，各终端用户
• 医院
  • 简介
  • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
• 诊所
• 其他

第10章 胆囊治疗市场-各地区

• 简介
  • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)，各地区
  • 市场魅力指数，各地区
• 北美
• 欧洲
• 南美
• 亚太地区
• 中东·非洲

第11章 胆囊治疗市场-竞争情形

• 主要的发展与策略
• 企业占有率分析
• 产品的基准

第12章 胆囊治疗市场-企业简介

• Boston Scientific Corporation
• Intuitive Surgical
• Stryker
• Medtronic
• Dornier MedTech
• B. Braun Melsungen AG
• Allergan, Inc.
• Photocure ASA
• Skylar Surgical Instruments
• Olympus Corporation

第13章 胆囊治疗市场-DataM

Market Overview

The global gallbladder treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

The gallbladder is a small pear-shaped organ beneath an individual's liver. This organ aids in the storage of bile produced by the liver and the transfer of that bile through a duct into the small intestine.

Market Dynamics

The factors influencing the global gallbladder treatment market are the increasing technological advancements and the growing prevalence of gallbladder problems.

The increasing technological advancements are expected to drive the global gallbladder treatment market in the forecast period

Gallstones are usually treated by removing the gallbladder surgically. The gallbladder is surgically removed in a cholecystectomy. In most cases (90 percent), this surgery can be done laparoscopically, a less invasive technique that results in less post-operative pain and a faster recovery than traditional cholecystectomy. Gallstones in the bile ducts may need to be removed even if there are no symptoms. Endoscopic retrograde cholangiopancreatography (ERCP) is a popular procedure. Because it uses several small incisions rather than one large one, laparoscopic cholecystectomy is minimally invasive. A laparoscope is a small tube that houses a camera. This surgical tool is inserted through a single incision. Due to the camera, a doctor can see the gallbladder on a TV screen. A second, smaller incision is used to remove the gallbladder. Another minimally invasive option for removing gallstones is an endoscopic retrograde cholangiopancreatography (ERCP) procedure. The endoscope is a tube-shaped instrument. UCLA researchers have discovered the best way to image the bile ducts during gallbladder removal surgeries using a tried and safe dye and a real-time near-infrared florescence laparoscopic camera. This finding will make the procedure much safer for the hundreds of thousands of people who have it every year. When surgeons examine the liver and surrounding anatomy laparoscopically, the new imaging procedure can be used.

Limitations associated with gallbladder treatment are expected to hamper the market growth

The patient may get an infection after the gallbladder is removed via surgery. Antibiotics may be required if there is pain, swelling, redness, and pus at the incision. Bile leakage is extremely uncommon; only 1% of people with gallbladder removed experience this problem. Other complications include injuries to the bile duct, intestine, bowel, or blood vessels, which may necessitate additional surgery. Damage to the common bile duct is the most feared and fatal cholecystectomy complication. Bile duct injuries became more common with the introduction of laparoscopic cholecystectomy, but as experience and training in minimally invasive surgery have improved, the incidence of this complication has decreased.

COVID-19 Impact Analysis

Gallbladder inflammation, which results in gangrene in COVID patients, is common in people who have gallstones. Because gallbladder epithelial cells are similar to bile duct cells and have a high concentration of ACE2 receptors, they can be a target for the SARS-CoV-2 virus or the body's dysregulated immune response to the virus resulting in severe gallbladder inflammation. Unfortunately, this isn't the first time post-COVID gangrene has been reported. Some cases of gangrene were discovered in patients who had recovered from COVID during the peak of the second wave. Doctors warn that the high level of inflammation and attack unleashed by the SARS-COV-2 virus increases the risk of gangrene. The lungs are the primary site of COVID-19 infection because they have the most ACE2 receptors, which the virus uses to bind human cells. The gastrointestinal tract (bile duct, gall bladder, and associated structures) has the most ACE2 receptors after the lungs. Hence, the gallbladder treatment market is expected to be impacted by covid-19.

Segment Analysis

Based on disease type, the gallstones segment is expected to dominate the market growth

Gallstones are very common, affecting 10 to 15% of the population in the United States, or nearly 25 million people. Approximately a quarter of the nearly 1 million people diagnosed with gallstones each year will require treatment, which is typically surgery. Cholecystectomy with an open incision. To remove the gallbladder, the doctor makes larger cuts in the stomach. The doctor may use ERCP to locate and remove gallstones in bile ducts before or during surgery. Cholecystectomy is performed laparoscopically. This is the most common gallstone surgery. A laparoscope is a narrow tube that a doctor inserts into the belly through a small cut. It has a camera, a light, and instruments. Another small cut is used to remove the gallbladder. Recent advancements in gallbladder (GB) gallstones (GS) elective treatments have provided many options that may be entering a new therapeutic era. Significantly symptomatic gallstones, as well as GS complications, require treatment. Some experts predicted that surgical cholecystectomy would become the gold standard with many nonoperative options available. However, such treatments are only palliative, leaving a "guilty" gallbladder in place in the presence of lithogenic bile, which invites to recurrence of GS.

Geographical Analysis

North America region is expected to hold the largest market share in the global gallbladder treatment market

The growing prevalence of gallbladder problems and better healthcare facilities in this region is expected to drive the market growth.

Gallstones are a major health issue in developed societies, affecting 10% to 15% of the adult population, implying that 20 to 25 million Americans have (or will have) gallstones. Gallstones are very common, affecting 10 to 15% of the population in the United States, or nearly 25 million people. Approximately a quarter of the nearly 1 million people diagnosed with gallstones each year will require treatment, which is typically surgery. Cholecystectomy, or gallbladder removal surgery, is one of the most common procedures performed on adults in the United States. The gallbladder is not a necessary organ, which means one can live a normal life without it.

Competitive Landscape

The global gallbladder treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Boston Scientific Corporation, Intuitive Surgical, Stryker, Medtronic, Dornier MedTech, B. Braun Melsungen AG, Allergan, Inc., Photocure ASA, Skylar Surgical Instruments, Olympus Corporation

Boston Scientific Corporation

Overview: Boston Scientific Corporation is a medical device manufacturer that specializes in interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, and endoscopy, oncology, urology, and gynaecology.

Product Portfolio: The Hot AXIOS Stent and Electrocautery-Enhanced Delivery System are indicated for use in the transgastric or transduodenal endoscopic drainage of the following conditions walled-off necrosis or a pancreatic pseudocyst with a fluid content of less than 70%, gallbladder in high-risk or surgically unsuitable patients with acute cholecystitis and patients with biliary obstruction due to a malignant stricture, the bile duct after a failed ERCP.

Why Purchase the Report?

Visualize the composition of the global gallbladder treatment market segmentation by disease, treatment, and end user, highlighting the key commercial assets and players.

Identify commercial opportunities in global gallbladder treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global gallbladder treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global gallbladder treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Gallbladder Treatment Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Gallbladder Treatment Market- Market Definition and Overview

3. Gallbladder Treatment Market- Executive Summary

• 3.1. Market Snippet By Disease
• 3.2. Market Snippet By Treatment
• 3.3. Market Snippet By End User
• 3.4. Market Snippet By Region

4. Gallbladder Treatment Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The increasing technological advancements
  • 4.1.2. Restraints:
    • 4.1.2.1. Limitations associated with gallbadder treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Gallbladder Treatment Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Gallbladder Treatment Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Gallbladder Treatment Market- By Disease

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
• 7.3. Market Attractiveness Index, By Disease
  • 7.3.1. Gallstones
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Cholecystitis
  • 7.3.3. Biliary Colic
  • 7.3.4. Cholelithiasis
  • 7.3.5. Gallbladder Polyps
  • 7.3.6. Gall bladder Cancer
  • 7.3.7. Other

8. Gallbladder Treatment Market-By Treatment

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
• 8.3. Market Attractiveness Index, By Treatment
  • 8.3.1. Surgery
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.1.1.3. Cholecystectomy
    • 8.3.1.1.4. Lithotripsy
    • 8.3.1.1.5. Other
  • 8.3.2. Drugs
  • 8.3.3. Others

9. Gallbladder Treatment Market- By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Clinics
• 9.4. Other

10. Gallbladder Treatment Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Gallbladder Treatment Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Gallbladder Treatment Market- Company Profiles

• 12.1. Boston Scientific Corporation*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Intuitive Surgical
• 12.3. Stryker
• 12.4. Medtronic
• 12.5. Dornier MedTech
• 12.6. B. Braun Melsungen AG
• 12.7. Allergan, Inc.
• 12.8. Photocure ASA
• 12.9. Skylar Surgical Instruments
• 12.10. Olympus Corporation

LIST NOT EXHAUSTIVE

13. Gallbladder Treatment Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us